Nexalin Technology Inc.
2.74
0.23 (9.16%)
At close: Jan 14, 2025, 3:59 PM
2.75
0.44%
After-hours Jan 14, 2025, 07:25 PM EST
undefined%
Bid 2.8
Market Cap 36.45M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.61
PE Ratio (ttm) -4.49
Forward PE n/a
Analyst Buy
Ask 3
Volume 740,997
Avg. Volume (20D) 1,817,800
Open 3.00
Previous Close 2.51
Day's Range 2.60 - 3.11
52-Week Range 0.25 - 4.49
Beta undefined

About NXL

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various m...

Sector Healthcare
IPO Date Sep 16, 2022
Employees 6
Stock Exchange NASDAQ
Ticker Symbol NXL

Analyst Forecast

According to 1 analyst ratings, the average rating for NXL stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 9.49% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Nexalin Technology Inc. is scheduled to release its earnings on Mar 26, 2025, after market closes.
Analysts project revenue of $30.00K, reflecting a 46.08% YoY growth and earnings per share of -0.12, making a 20.00% increase YoY.
2 months ago · Source
+26.91%
Nexalin Technology shares are trading higher after... Unlock content with Pro Subscription
2 months ago · Source
+20.95%
Nexalin Technology shares are trading higher after the company announced the launch of its Gen-3 Halo Headset clinical trial for at-home mTBI treatment through a partnership with UC San Diego and San Diego VA.